Angiogenesis-Targeted 68Ga-DOTA-RGD2 PET/CT Imaging: a Potential Theranostic Application in the Case of Chondrosarcoma
Tóm tắt
Chondrosarcoma is a cartilaginous tumor of mesenchymal origin. The histology and grade of the tumor determine the chances of relapse and survival. These tumors usually respond poorly to chemo-radiotherapy in cases of non-resectable and recurrent disease. 18F-FDG PET/CT has been used in evaluation of recurrence. However, these tumors show only mild to moderate FDG avidity due to their lower mitotic activity and large acellular matrix. These tumors are known to have a high degree of angiogenesis, especially in those of higher grade. We present a case of a 53-year-old man with grade II chondrosarcoma of the left femur showing only mild avidity on 18F-FDG PET/CT but showing moderate to intense tracer avidity on 68Ga-DOTA-RGD2 PET/CT. This may enable the use of angiogenesis-targeted positron and beta-emitting radiopharmaceuticals as a potentially new theranostic alternative treatment in cases of refractory metastatic chondrosarcoma.
Tài liệu tham khảo
Riedel RF, Larrier N, Dodd L, et al. The clinical management of chondrosarcoma. Curr Treat Options in Oncol. 2009;10:94–106.
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7.
Vadi SK, Mittal BR, Gorla AKR, Sood A, Basher RK, Sood A, et al. 18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with suspected recurrence of chondrosarcoma. Clin Nucl Med. 2018;43:87–93.
Feldman F, Van Heertum R, Saxena C, Parisien M. 18FDG-PET applications for cartilage neoplasms. Skelet Radiol. 2005;34:367–74.
Kalinski T, Sel S, Kouznetsova I, Röpke M, Roessner A. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract. 2009;205:339–45.
Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Werneck da Cunha I, Soares FA, et al. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am. 2010;92:1738–46.
Horton A. The avp3 integrin “vitronectin receptor.” Int J Biochem Cell Biol 1997;29:721–725.
Niu G, Chen X. RGD PET: from lesion detection to therapy response monitoring. J Nucl Med. 2016;57:501–2.
Eo JS, Jeong JM. Angiogenesis imaging using 68Ga-RGD PET/CT: therapeutic implications. Semin Nucl Med. 2016;46:419–27.
Banerjee S, Pillai MRA, Knapp FF. 177Lu therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115:2934–74.